Clinical outcomes in the scholarly study were presented on the 2019 Culture for Gynecologic Oncology Annual meeting in Honolulu, Hawaii
Clinical outcomes in the scholarly study were presented on the 2019 Culture for Gynecologic Oncology Annual meeting in Honolulu, Hawaii. Contending interests: DZ reviews clinical study support to his institution from Astra Zeneca and Genentech; personal/consultancy costs from Merck, Synlogic Therapeutics, Biomed Valley Discoveries, Trieza Therapeutics, Tesaro, Bristol Myers Squibb, and Agenus; and travel support from Genenetech. (DCR), progression-free success (PFS), overall success (OS), and basic safety. Results In the full total evaluable people (n=10), zero sufferers achieved a target response as evaluated by Response Evaluation Requirements In Solid Tumors (RECIST) V.1.1, producing a confirmed ORR of 0%. Of be aware, there have been two sufferers who attained an unconfirmed PR. The DCR by RECIST V.1.1 was 60% (0% complete response, 0% partial response, 60% steady Chlorothricin disease). Median PFS…